pre-IPO PHARMA

COMPANY OVERVIEW

Excision BioTherapeutics, Inc. is a biotechnology company developing CRISPR-based therapies to cure viral infectious diseases. Excision is focused on improving the lives of chronically ill patients by eliminating viral genomes from infected individuals. By using CRISPR in unique ways, the company has already demonstrated the first functional cure for HIV in animals. Excision is developing technologies and IP developed at Temple University and U.C. Berkeley. Excision is located in Oakland, California and is supported by ARTIS Ventures, Norwest Venture, SilverRidge Venture Partners, Oakhouse Partners, and Gaingels.


LOCATION

  • Philadelphia, PA, USA
  • Tarrytown, NY, USA
  • Shenzhen, Guangdong, China
  • Melbourne, Victoria, Australia

  • THERAPEUTIC AREAS

  • Infectious Disease

  • WEBSITE

    https://www.excisionbio.com/


    CAREER WEBSITE

    https://www.excisionbio.com/careers


    SOCIAL MEDIA


    INVESTORS

    artis-ventures gaingels oakhouse-partners siliver-ridge-capital-partners


    PRESS RELEASES


    Jun 7, 2022

    Excision BioTherapeutics to Participate in the Jefferies Healthcare Conference on Thursday, June 9, 2022 at 2:00 p.m. ET


    May 17, 2022

    Excision BioTherapeutics to Present Preclinical and Bioinformatic Data Showing Robust and Specific Editing of HIV Proviral DNA with EBT-101 at the ASGCT 25th Annual Meeting


    Jan 27, 2022

    Excision BioTherapeutics Initiates Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure for HIV


    Oct 12, 2021

    Excision BioTherapeutics Expands Management Team with Three Key Appointments


    Oct 12, 2021

    Excision BioTherapeutics Expands Management Team with Three Key Appointments


    For More Press Releases


    Google Analytics Alternative